Live feed08:30:00·21dPRReleaseUltragenyx Announces U.S. FDA Acceptance of BLA Resubmission for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)RARE· Ultragenyx Pharmaceutical Inc.Health CareOriginal source
